Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity

C M Celluzzi1, L D Falo

  • 1Department of Dermatology, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.

The Journal of Investigative Dermatology
|May 1, 1997
PubMed
Summary

Epidermal dendritic cells (eDCs) can effectively stimulate CD8+ cytotoxic T lymphocytes (CTLs) to fight tumors. Vaccination with OVA peptide-pulsed eDCs protected mice against melanoma, highlighting their potential in anti-tumor immunity strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In silico programming of degradable microparticles to hide and then reveal immunogenic payloads in vivo.

Journal of materials chemistry. B·2020
Same author

Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice.

Allergy·2016
Same author

The immunology of DNA vaccines.

Methods in molecular medicine·2011
Same author

Novel approach to gene expression profiling in Sézary syndrome.

The British journal of dermatology·2010
Same author

Transcriptional IL-15-directed in vivo DC targeting DNA vaccine.

Gene therapy·2009
Same author

Multicenter study on in vitro characterization of dendritic cells.

Cytotherapy·2008

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Research

Background:

  • Dendritic cells (DCs) are potent antigen-presenting cells (APCs) crucial for initiating immune responses.
  • Cytotoxic T lymphocytes (CTLs) are vital for combating tumors and viral infections.
  • Epidermal dendritic cells (eDCs), or Langerhans cells, are known to stimulate CD4+ T cell immunity but their role in CD8+ CTL induction was unclear.

Purpose of the Study:

  • To determine if epidermal dendritic cells (eDCs) can induce tumor-specific CD8+ cytotoxic T lymphocyte (CTL) immunity.
  • To evaluate the efficacy of eDCs in immunization strategies against tumors.
  • To compare the CTL-inducing capacity of eDCs with bone marrow-derived dendritic cells (BmDCs).

Main Methods:

  • Subcutaneous immunization of mice with ovalbumin (OVA) peptide-pulsed eDCs.

Related Experiment Videos

  • Assessment of OVA-specific CD8+ CTL induction and their cytotoxic activity against OVA-expressing targets.
  • Challenging vaccinated mice with an OVA-expressing melanoma (MO5) to evaluate protective immunity.
  • Comparing the antigen-presenting cell (APC) capacity of eDCs and BmDCs based on cell surface marker expression (MHC class II and B7.2) and protective immunity.

    • Main Results:

    • OVA peptide-pulsed eDCs successfully induced OVA-specific CD8+ CTLs capable of lysing OVA-expressing target cells.
    • Mice vaccinated with OVA peptide-pulsed eDCs were completely protected against a subsequent challenge with OVA-expressing melanoma MO5.
    • The induction of CTL-mediated immunity by eDCs was dose-dependent.
    • eDCs demonstrated an APC capacity comparable to BmDCs in inducing protective anti-tumor immunity.

    Conclusions:

    • Epidermal dendritic cells (eDCs) are potent inducers of antigen-specific CD8+ CTL-mediated immunity.
    • eDCs represent a promising target for antigen delivery strategies aimed at developing effective anti-tumor and antiviral immunizations.
    • These findings support the use of eDCs in novel therapeutic and preventative vaccine approaches against cancer and viral diseases.